Effect of nicorandil on myocardial ischemic preconditioning in patients with coronary heart disease and type 2 diabetes mellitus

DOI: https://doi.org/10.29296/25877305-2018-10-18
Download full text PDF
Issue: 
10
Year: 
2018

Professor Zh. Sizova, MD; V. Zakharova, Candidate of Medical Sciences; N. Kozlova I.M. Sechenov First Moscow State Medical University (Sechenov University)

The possibilities of pharmacological correction of the coronary reserve with traditional nitroso-containing drugs and the potassium channel activator nicorandil and their effects on myocardial ischemic preconditioning (IP) were compared in patients with ischemic heart disease (CHD) and type 2 diabetes mellitus (T2DM). In patients with CHD and T2DM, nicorandil is the drug of choice for long-term treatment, which is more effective than traditional nitroso drugs and is able to initiate myocardial IP. Nicorandil is effective in correcting endothelial dysfunction, without causing the development of tolerance and without reducing the efficacy in the co-use of glucose-lowering therapy.
Keywords: 
cardiology
coronary heart disease
type 2 diabetes mellitus
ischemic preconditioning
endothelial dysfunction
nicorandil
Kordinik

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Rezkalla S., Kloner R. Preconditioning in humans // Heart Fail Rev. – 2007; 12: 201–6.
  2. Gostischev R.V., Soboleva G.N., Samko A.N. i dr. Farmakologicheskoe prekonditsionirovanie. V fokuse – nikorandil // Ros. kardiol. zhurn. – 2017; 8: 114–21. DOI: 10.15829/1560-4071-2017-8-114-121.
  3. Dedov I.I., Shestakovoj M.V., Majorova A.Ju. Algoritmy spetsializirovannoj meditsinskoj pomoschi bol'nym saharnym diabetom // Saharnyj diabet. – 2017; 20 (1S): 1–112.
  4. Bulahova E.Ju., Korennova O.Ju., Kondrasheva M.N. i dr. Klinicheskie preimuschestva terapii nikorandilom v sravnenii s izosorbid-5-mononitratom u bol'nyh IBS // Serdtse. – 2013; 2 (12): 83–7.
  5. Rjabihin E.A., Mozhejko M.E., Krasil'nikova Ju.A. Effektivnost' i bezopasnost' dlitel'noj terapii nikorandilom bol'nyh stabil'noj stenokardiej // Serdtse. – 2014; 13 (3): 151–5.
  6. Jiang J., Li Y., Zhou Y. et al. Oral nicorandil reduces ischemic attacks in patients with stable angina: A prospective, multicenter, open-label, randomized, controlled study // Int. J. Cardiol. – 2016; 224: 183–7.
  7. Voronina V.P., Martsevich S.Ju., Kutishenko N.P. i dr. Otsenka antiishemicheskogo i antianginal'nogo effektov nikorandila s pomosch'ju nagruzochnyh testov na tredmile v ramkah issledovanija KVAZAR // Ros. kardiol. zhurn. – 2017; 2: 91–7.
  8. Ametov A.C., Orlov V.A. Osobennosti bezbolevoj ishemii miokarda u bol'nyh insulinnezavisimym saharnym diabetom // Problemy endokrinologii. – 2007; 5: 19–22.
  9. Aleksandrov A.A., Bondarenko I.Z., Kuharenko S.S. i dr. Saharnyj diabet i ishemicheskaja bolezn' serdtsa: poiski reshenija // Saharnyj diabet. – 2005; 3: 34–8.
  10. Mkrtumjan A.M. Uroven' glikemii kak faktor riska serdechno-sosudistyh zabolevanij // Saharnyj diabet. – 2010; 3: 80–2.
  11. Holman R., Paul S., Bethel M. et al. 10-Year Follow–up of Intensive Glucose Control in Type 2 Diabetes // N. Engl. J. Med. – 2008; 359: 1577–89.
  12. Pashentseva A.V., Verbovoj A.F. Saharosnizhajuschaja terapija i serdechno-sosudistaja bezopasnost' // Farmateka. – 2015; 13: 32–7.
  13. Sharonova L.A., Verbovoj A.F., Kosareva O.V. Rol' preparatov sul'fonilmocheviny v lechenii saharnogo diabeta 2 tipa // Med. sovet. – 2016; 3: 6–9.
  14. Vatutin N.T., Kalinkina N.V., Kolesnikov V.S. i dr. Fenomen prekonditsionirovanija // Serdtse. – 2013; 12 (4): 199–206.
  15. Baxter G. Role of adenosine in delayed preconditioning of myocardium // Cardiovasc. Res. – 2002; 55: 483–94.
  16. Lee T., Chou T. Impairment of myocardial protection in type 2 diabetic patients // J. Clin. Endocrinol. Metab. – 2003; 88: 531–7.
  17. Strojek K., Yoon K., Hruba V. et al. Effect of dapagliflozin in patients with type 2 diabetes who have in adequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial // Diabetes, Obesity and Metabolism. – 2011; 13: 10